XML 51 R39.htm IDEA: XBRL DOCUMENT v3.25.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Concentration Risk [Line Items]          
Rebate receivable $ 34,000   $ 34,000   $ 54,400
Investments in equity-method investees 26,000   26,000   $ 24,500
Equity in earnings of joint ventures $ 1,400 $ 1,400 3,124 $ 2,530  
Distributions received from the investees     $ 1,600 $ 750  
Revenue from Contract with Customer Benchmark | Governmental Healthcare Programs | Government Healthcare Programs          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 12.00% 11.00% 12.00% 12.00%  
Accounts Receivable, Benchmark | Governmental Healthcare Programs | Government Healthcare Programs          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent)     11.00%   11.00%
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors | Four Vendors          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 59.00% 68.00% 67.00% 67.00%  
Largest Payer | Revenue from Contract with Customer Benchmark | Company's Largest Payer          
Concentration Risk [Line Items]          
Concentration ​risk (as a percent) 15.00% 14.00% 15.00% 14.00%  
Joint Venture          
Concentration Risk [Line Items]          
Distributions received from the investees $ 1,600 $ 0 $ 1,600 $ 800